SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0001415889-23-011171
Filing Date
2023-07-17
Accepted
2023-07-17 18:00:44
Documents
2
Period of Report
2023-07-11

Document Format Files

Seq Description Document Type Size
1 form3-07172023_100740.html 3  
1 form3-07172023_100740.xml 3 1732
2 ex24-07172023_100740.htm EX-24 4785
  Complete submission text file 0001415889-23-011171.txt   7976
Mailing Address 4995 BRADENTON AVENUE SUITE 240 DUBLIN OH 43017
Business Address 4995 BRADENTON AVENUE SUITE 240 DUBLIN OH 43017 6147937500
NAVIDEA BIOPHARMACEUTICALS, INC. (Issuer) CIK: 0000810509 (see all company filings)

IRS No.: 311080091 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2835 In Vitro & In Vivo Diagnostic Substances

Mailing Address 4995 BRADENTON AVE SUITE 240 DUBLIN OH 43017
Business Address
Moss Dana J (Reporting) CIK: 0001985665 (see all company filings)

Type: 3 | Act: 34 | File No.: 001-35076 | Film No.: 231092540